{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:07:10Z","timestamp":1770988030320,"version":"3.50.1"},"reference-count":32,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: Chronic kidney disease (CKD) is traditionally viewed as a condition marked by a progressive reduction in kidney function leading to the need for kidney dialysis or transplantation. The estimated prevalence of CKD in adults in Puerto Rico is ~20% higher than that of the overall United States (US). To address the disproportionately high rate of CKD in Puerto Rico, we created a multidisciplinary chronic disease management (CDM) program targeting CKD and diabetes mellitus (DM), the leading CKD risk factor. Methods: Over 7200 eligible enrollees in a Puerto Rico-Managed Medicare Program participated in a CDM program targeting individuals with CKD or DM as determined by administrative review. Evaluations were conducted on 4068 program participants with baseline glomerular filtration rate (eGFR) and codifying CKD stage by eGFR. A dietitian\/nurse team provided dietary and lifestyle recommendations to the patient\/family and a nephrologist\/endocrinologist made diabetes and CKD recommendations to the primary care provider. Findings on 2095 participants with Stages 1\u20133 CKD with follow-up eGFR at least 6 months but less than 2 years after baseline are presented. Results: At baseline, the mean age was 74 years (range 30\u2013101), 59% of patients were female and mean duration of follow-up from initial evaluation to second evaluation was 407 days (\u00b1159 days SD). Most participants had Stage 2 CKD (34.8%), followed by CKD Stage 1 and 3 (33.5 and 31.7%). During the follow-up period, 55.9% of participants with Stage 1 CKD remained in Stage 1, 84.9% of patients with Stage 2 remained in Stage 2 or regressed to Stage 1, while 96.1% of patients with Stage 3 remained in Stage 3 or regressed to Stage 2. Only 15.1% of patients in Stage 2 progressed to Stage 3 and 3.9% of patients in Stage 3 progressed to Stage 4 or 5. A secondary analysis comparing all 665 CDM Stage 3 participants to 117,249 historical controls found CDM participants demonstrated a higher rate of regression (20.3% vs. 15.2%; absolute difference +5.1 percentage points; p = &lt;0.01) and a lower rate of progression (3.9% vs. 15.3%; absolute difference \u221211.4 percentage points; p &lt; 0.001). Conclusions: Early findings of a multidisciplinary CDM intervention indicate that 79% of participants with CKD Stages 1\u20133 by eGFR had stabilized or improved CKD status. Comparison to a randomized control group to better assess for causality and longer-term CDM program follow-up on CKD status and clinical outcomes is warranted.<\/jats:p>","DOI":"10.3390\/ijerph23020237","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:06:59Z","timestamp":1770984419000},"page":"237","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preliminary Findings of a Chronic Disease Management Program in Medicare Advantage Enrollees with Mild to Moderate Kidney Disease"],"prefix":"10.3390","volume":"23","author":[{"given":"Trevon","family":"Morales","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubette","family":"Harford","sequence":"additional","affiliation":[{"name":"Atlantis HealthCare Inc., Trujillo Alto, PR 00978, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulcie","family":"Kermah","sequence":"additional","affiliation":[{"name":"School of Medicine, Charles R Drew University of Medicine and Science, Los Angeles, CA 90059, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Flaque","sequence":"additional","affiliation":[{"name":"Atlantis HealthCare Inc., Trujillo Alto, PR 00978, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Camacho","sequence":"additional","affiliation":[{"name":"Atlantis HealthCare Inc., Trujillo Alto, PR 00978, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damaris","family":"Vasquez","sequence":"additional","affiliation":[{"name":"Atlantis HealthCare Inc., Trujillo Alto, PR 00978, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Schmidt","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Hern\u00e1ndez-Roses","sequence":"additional","affiliation":[{"name":"MCS Healthcare Holdings, LLC, San Juan, PR 00916-1919, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"O\u2019Drobinak","sequence":"additional","affiliation":[{"name":"MCS Healthcare Holdings, LLC, San Juan, PR 00916-1919, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3071-0700","authenticated-orcid":false,"given":"Keith C.","family":"Norris","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jama.2025.18457","article-title":"Classification and Risk Assessment of Chronic Kidney Disease","volume":"335","author":"Gunning","year":"2025","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Li, Y., Barve, K., Cockrell, M., Agarwal, A., Casebeer, A., Dixon, S.W., and Poonawalla, I. (2023). Managing comorbidities in chronic kidney disease reduces utilization and costs. BMC Health Serv. Res., 23.","DOI":"10.1186\/s12913-023-10424-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2337\/cd23-0063","article-title":"Diabetic Kidney Disease Prevention Care Model Development","volume":"42","author":"ElSayed","year":"2024","journal-title":"Clin. Diabetes"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.kisu.2021.01.005","article-title":"International Society of Nephrology Global Kidney Health Atlas: Structures, organization, and services for the management of kidney failure in Latin America","volume":"11","author":"Wainstein","year":"2021","journal-title":"Kidney Int. Suppl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100385","DOI":"10.1016\/j.xkme.2021.09.003","article-title":"CKD Prevalence Among Patients with and Without Type 2 Diabetes: Regional Differences in the United States","volume":"4","author":"Feng","year":"2022","journal-title":"Kidney Med."},{"key":"ref_6","unstructured":"United States Renal Data System (2024). 2024 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/jamainternmed.2016.1144","article-title":"Disparities in Health Care in Puerto Rico Compared with the United States","volume":"176","author":"Colon","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115888","DOI":"10.1016\/j.socscimed.2023.115888","article-title":"On leaving: Coloniality and physician migration in Puerto Rico","volume":"325","author":"Padilla","year":"2023","journal-title":"Soc. Sci. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1159\/000519758","article-title":"Disparities in Chronic Kidney Disease Progression by Medicare Advantage Enrollees","volume":"52","author":"Diamantidis","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamainternmed.2016.0267","article-title":"Quality of Care for White and Hispanic Medicare Advantage Enrollees in the United States and Puerto Rico","volume":"176","author":"Leyva","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"World Medical Association (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA J. Am. Med. Assoc., 310, 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C\u2013Based Equations to Estimate GFR without Race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.ajkd.2024.08.003","article-title":"KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD","volume":"85","author":"Navaneethan","year":"2024","journal-title":"Am. J. Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"Khunti","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1681\/ASN.0000000000000300","article-title":"Role of Age and Competing Risk of Death in the Racial Disparity of Kidney Failure Incidence after Onset of Chronic Kidney Disease","volume":"35","author":"Yan","year":"2024","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2112828","DOI":"10.1001\/jamanetworkopen.2021.12828","article-title":"Progression and Regression of Chronic Kidney Disease by Age Among Adults in a Population-Based Cohort in Alberta, Canada","volume":"4","author":"Liu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/j.ackd.2021.02.001","article-title":"Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned","volume":"28","author":"Neumiller","year":"2021","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/gfac283","article-title":"Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease","volume":"38","author":"Nee","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/1475-6773.13977","article-title":"Racial and ethnic disparities in access to and enrollment in high-quality Medicare Advantage plans","volume":"58","author":"Park","year":"2023","journal-title":"Health Serv. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/1475-6773.14150","article-title":"Assessing the difference in racial and ethnic disparities in access to and use of care between Traditional Medicare and Medicare Advantage","volume":"58","author":"Gangopadhyaya","year":"2023","journal-title":"Health Serv. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.2105\/AJPH.2024.307585","article-title":"United States Federal Policies Contributing to Health and Health Care Inequities in Puerto Rico","volume":"114","author":"McSorley","year":"2024","journal-title":"Am. J. Public Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1353\/hpu.2017.0111","article-title":"Regional Variations in the Interpretation of the End-Stage Renal Disease Thirty-Month Coordination Period: Potential Implications for Patient Care","volume":"28","author":"Harford","year":"2017","journal-title":"J. Health Care Poor Underserved"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e251949","DOI":"10.1001\/jamahealthforum.2025.1949","article-title":"Puerto Rico\u2019s Specialist Crisis\u2014A Wake-Up Call for Health Equity and Action","volume":"6","year":"2025","journal-title":"JAMA Health Forum"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MNH.0000000000000688","article-title":"Disparities in chronic kidney disease-the state of the evidence","volume":"30","author":"Rivera","year":"2021","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2215\/CJN.02020215","article-title":"Prevalence and Correlates of CKD in Hispanics\/Latinos in the United States","volume":"10","author":"Ricardo","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100636","DOI":"10.1016\/j.xkme.2023.100636","article-title":"Costs Associated With Progression of Mildly Reduced Kidney Function Among Medicare Advantage Enrollees","volume":"5","author":"Diamantidis","year":"2023","journal-title":"Kidney Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jama.2025.20835","article-title":"Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis","volume":"335","author":"Staplin","year":"2026","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_30","first-page":"13","article-title":"A Shrinking Primary Care Workforce in Puerto Rico","volume":"101","author":"Wilkinson","year":"2020","journal-title":"Am. Fam. Physician"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/fampra\/cmz092","article-title":"Pragmatic research: An introduction for clinical practitioners","volume":"37","author":"Holtrop","year":"2020","journal-title":"Fam. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dember, L.M. (2026). Designing Pragmatic Trials to Better Inform Nephrology Practice. J. Am. Soc. Nephrol., Online ahead of print.","DOI":"10.1681\/ASN.0000001029"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/23\/2\/237\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:08:09Z","timestamp":1770984489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/23\/2\/237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijerph23020237"],"URL":"https:\/\/doi.org\/10.3390\/ijerph23020237","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}